Which Health Care Stock Belongs in Your Portfolio?

There isn’t much to choose from in Canada, but with an aging population, this may be too good an opportunity to pass up.

| More on:
The Motley Fool

Health care is a sector that’s very underrepresented in Canada, with only two names in the S&P/TSX 60 index. By comparison, healthcare makes up about 12% of the S&P 500.

This is partly due to our public health care system, which eliminates the need for massive health insurance companies, so as Canadians we should be thankful. However, as investors, it presents a problem, because as populations age, healthcare companies stand to benefit immensely; it would be nice to try to take advantage of that in our portfolios.

On that note, below we take a look at Canada’s two large companies in the health care sector.

1. Valeant Pharmaceuticals

There is perhaps no Canadian company more polarizing than Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX). To the company’s credit, its shares have been on a tear recently, thanks to CEO Michael Pearson’s acquisition-first strategy. Over the past five years, the stock has returned 56% per year.

However, there are some big question marks about Valeant. The problems stem mainly from the company’s accounting, which gets very complicated due to the high level of acquisitions. In fact, the company itself reports financial measures such as “adjusted operating cash flow” and “cash earnings per share” that exclude many acquisition-related costs. On a reported basis, Valeant actually lost $2.70 per share last year. Some very smart people, such as famous short-seller Jim Chanos, are betting against the company.

There are also some very smart people who think the run won’t end. Chief among them is activist investor Bill Ackman of Pershing Square, who would become a major shareholder if Valeant’s acquisition of Allergan (NYSE: AGN) is successful. Mr. Ackman has been continually defending Valeant on television shows.

2. Catamaran

Less well-known is the pharmacy benefit manager Catamaran (TSX: CCT)(NASDAQ: CTRX). Despite being part of the S&P TSX/60, Catamaran makes all of its money in the United States, which allows the company to benefit from some very favourable trends.

One such trend is the increase in prescription drug spending as a result of the Affordable Care Act. The ACA will result in more people being covered by a health plan. This includes pharmacy benefits, as well as maximums on how much the patient has to cover for drugs out-of-pocket. Furthermore, the aging population will also drive drug spending — Americans are forecast to spend nearly $500 billion on drugs by 2020, a big increase over the $250 billion spent in 2009.

In addition, Catamaran does not have the same accounting issues as a company like Valeant, so if you’re simply looking to make a bet on the health care sector, this is the better stock of the two.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair holds no positions in any of the stocks mentioned in this article. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Happy family father of mother and child daughter launch a kite on nature at sunset

3 Soaring Stocks to Hold for the Next 20 Years

These three stocks are good bets for the long haul, given their healthy long-term growth prospects.

Read more »

grow dividends
Tech Stocks

Celestica Stock Is up 44% Since Earnings: What Investors Need to Know

Celestica continues to benefit from strong demand and production efficiencies, yet the stock remains undervalued.

Read more »

A plant grows from coins.

2 Dividend Stocks Paying 5% or More That Could Beat the Market in 2024 and Beyond 

Here are two top dividend stocks long-term investors may certainly want to consider for their yields and growth profiles right…

Read more »

edit Balloon shaped as a heart
Dividend Stocks

Love Value Stocks? 2 That Are Screaming Buys in May 2024

Patience can pay off by investing in these two value stocks with nice dividends and the potential to turn around.

Read more »

healthcare pharma
Tech Stocks

What’s Going on With WELL Health Stock?

WELL stock (TSX:WELL) made strong moves once again, with record earnings and even higher guidance for 2024.

Read more »

Senior Couple Walking With Pet Bulldog In Countryside
Dividend Stocks

2 Everlasting Canadian Stocks for Your RRSP

The Canadian National Railway (TSX:CNR) stock is worth owning for the long haul.

Read more »

money cash dividends
Stocks for Beginners

Is TD Stock the Best Dividend Stock for You?

Shares of TD stock (TSX:TD) plunged on the news of a money laundering probe. But could this mean it's a…

Read more »

exchange traded funds

New to Investing? Get Started With This Easy, Hands-Off Method

Vanguard S&P 500 Index ETF (CAD-hedged) (TSX:VSP) is a glorious first investment candidate for beginner investors.

Read more »